Hepatitis B virus (HBV) and its hepadnavirus relatives infect a wide range of vertebrates from 25 fish to human. Hepadnaviruses and their hosts have a long history of acquiring adaptive mutations. 26
Introduction 58
Over 250 million people are chronically infected worldwide with hepatitis B virus (HBV), and 59 hepatitis B resulted in 887,000 deaths in 2015 (1). HBV and its hepadnavirus relatives infect a wide 60 range of vertebrates, including fish, amphibians, reptiles, birds, and mammals (2-10). Phylogenetic 61 analyses suggest that the coevolutionary history of hepadnaviruses and their hosts spans hundreds of 62 millions of years (2, 6, 7, 9) . During the long-term coevolution of virus and host, host proteins that 63 interact directly with a virus accumulate adaptive mutations to permit escape from virus infection, 64 while viruses acquire mutations that overcome host barriers (11). In the course of this coevolutionary 65 "arms race", viruses continuously exert selective pressures on their host, thereby inducing multiple 66 adaptive mutations in the host genome (12). One of the best-known examples of such coevolution is 67 embodied by the conflict between (host-encoded) restriction factors and their (virus-encoded) viral 68 antagonists (11). Host restriction factors inhibit viral replication at different steps during virus 69 proliferation in the host. Conversely, viruses encode factors that antagonize the function of host 70 restriction factors and thereby circumvent the host's attempt to eliminate viruses (13). During the 71 course of long-term viral selective pressures, some host restriction factors evolve rapidly, a process 72 that is evidenced as a ratio of nonsynonymous to synonymous mutations in the host gene (the dN/dS 73 ratio) that exceeds 1 ("positive selection") (14). For example, host restriction factors against human 74 immunodeficiency virus type 1 (HIV-1), including tripartite motif-containing protein 5-alpha 75 (TRIM5) (15), apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) 76 (16), bone marrow stromal antigen 2 (BST2, also known as tetherin, CD317, and HM1.24) (17-20), 77 and SAM domain and HD domain 1 (SAMHD1) (21, 22), have been reported to exhibit rapid evolution 78 (dN/dS > 1), likely due to the selective pressure exerted by HIV-1 infection. Regarding the coevolution 79 of hepadnaviruses and host restriction factors, Abdul et al. recently reported an evolutionary analysis 80 of an HBV restriction factor, the Structural Maintenance of Chromosomes (Smc) 5/6 complex (23), a 81 5 complex originally identified based on its housekeeping function in genomic stability (24). However, 82
Abdul et al. did not detect a clear signature of positive selection that was suggested to be induced by 83 hepadnavirus infection. In contrast, Enard et al. reported that host proteins interacting with viruses 84 with a long history display higher rates of adaptive mutations (12); those authors showed that host 85 proteins reported to interact with HBV exhibited a strong signature of adaptation during a coevolution 86 with viruses, which was in a similar degree to that seen for HIV-1-interacting host proteins. However, 87 molecules subject to such a selective pressure by hepadnaviruses have not (to our knowledge) been 88 identified to date. 89
Hepadnaviruses infect their hosts in a highly species-specific manner; for instance HBV can 90 infect only humans, chimpanzees, and treeshrews, but not monkeys, including both Old-World and 91
New-World monkeys (25). The sodium taurocholate cotransporting polypeptide [NTCP, also 92 designated as solute carrier family 10A1 (SLC10A1)] was recently identified as a host factor that 93 functions as an HBV entry receptor; NTCP, which originally was characterized as a hepatic transporter 94 for the uptake of bile acids by hepatocytes, binds to the HBV envelope protein, notably to the preS1 95 region, thereby mediating viral entry into the host (26). NTCP has been suggested to be a key 96 determinant of the species-specificity of HBV, as primary monkey hepatocytes can support the 97 replication of intracellular HBV but not the entry of the virus into host cells (27), and complementation 98 the monkey cells with human NTCP (hNTCP) permits HBV entry and thereby the whole infection 99 cycle both in cell culture and in vivo (28, 29). These results indicate that the inability of monkey Ntcp 100 to support HBV infection serves as the species barrier preventing HBV infection in monkey. However, 101 the evolutionary relationship between NTCP sequences in different species and susceptibility to 102 hepadnavirus infection has not been analyzed previously. Virus entry receptors generally have their 103 own original function in cellular physiology. Thus their sequences typically are conserved during 104 evolution to maintain their functional profile, showing a dN/dS < 1 that indicates negative selection 105 6 (30). Indeed, transferrin receptor (TfR1), which serves as an entry receptor for arenaviruses and mouse 106 mammary tumor virus (31), exhibit such evolutionary negative selection across their entire sequences. 107
Interestingly, however, a small percentage of positions in the TfR1 coding sequence is rapidly evolving 108 under positive selection, and these sites were shown to correspond to a virus-binding surface (31). In 109 another example, the Niemann-Pick disease, type C1 (NPC1), a receptor for filovirus, shows a similar 110 evolutionary property (32). These data strongly suggest that virus infection serve as a pressure for the 111 evolution of viral entry receptors. In addition, positive selection sites on virus entry receptors can 112 provide critical information, permitting the identification of the receptor domains that interface with 113 the virus. However, to our knowledge, there have been no reports of such an evolutionary analysis for 114 a hepadnavirus receptor. 115
In this study, we focused on the phylogenetic analyses of hepadnaviruses and NTCP based on 116 molecular evolutionary analyses to detect positive selection sites, and investigated the biological 117 significance of NTCP sequence changes using virological experimental assays in our cell culture model 118 (33). Evolutionary analyses of the NTCPs from 20 mammalian species revealed that NTCP was highly 119 conserved among these mammals, but interestingly identified several sites that were subject to positive 120 selection. Among these positive selection sites, the amino acid (aa) at NTCP residue 158 determined 121 the HBV host species-specificity: Our virological experiments showed that a single substitution 122 converting aa 158 of human NTCP to the corresponding aa of cynomolgus macaque Ntcp completely 123 negated the protein's ability to mediate viral infection, whereas a cynomolgus macaque Ntcp protein 124 mutated to carry the hNTCP aa 158 rendered macaque Ntcp susceptible to the virus, suggesting that 125 this site regulates viral susceptibility. Moreover, aa 158 of NTCP was shown to mediate viral 126 attachment to the host cell surface. In a manner analogous to TfR1 and NPC1, these data suggest that 127 NTCP receives an evolutionary pressure by virus infection, which provides the first evidence in a 128 molecular level for coevolution between hepadnaviruses and hosts. inferred by at least one of the three evolutionary analyses as summarized in Table 3 . We next addressed whether the amino acids encoded by these sites are involved in susceptibility 159 to HBV infection. We prepared HepG2 cells transiently expressing hNTCP or a series of single-mutant 160 variants in which a single amino acid was replaced by the corresponding macaque residue (S142T, 161 K157G, G158R, V160I, and L165P) ( Figure 3A ). Similarly, we produced HepG2 cells expressing a 162 variant of hNTCP in which aa 157-165 were replaced by the corresponding macaque sequence 163
[designated hNTCP(m157-165)]; this substitution has been reported to abrogate NTCP's receptor 164 function (26) ( Figure 3A ). At 24 h after transfection, protein expression of NTCP or its variants was 165 confirmed by immunoblotting of cell lysates. As shown in Figure 3A , the mutant hNTCPs were 166 expressed at levels equivalent to that of wild-type hNTCP, except for hNTCP-L165P, which had much 167 lower protein expression ( Figure 3A ). To further validate whether each of the NTCP variants 168 maintained its functional properties as a bile acid transporter, we also measured NTCP-mediated uptake 169 of [ 3 H]-taurocholic acid in these cells. All NTCP variants, including hNTCP-L165P, possessed the 170 capacity to uptake bile acid, retaining at least 40 % of the wild-type activity and providing activity 6-171 to 24-fold that of background (assessed under sodium-free conditions) ( Figure 3B ). Thus, all of the 172 hNTCP variant-expressing HepG2 cell lines in this experiment retained NTCP functions. 173
We then analyzed the ability of these cell lines to support HBV infection. Specifically, an HBV 174 infection assay was performed (per Materials and Methods) (33) to evaluate the cells' susceptibility to 175 HBV infection by detecting intracellular hepatitis B core antigen (HBcAg) at 13 days post-inoculation 176 9 by immunofluorescence analysis ( Figure 4A , right pictures, red, "DMSO"). The detected levels of 177
HBcAg were normalized to the expression level of NTCP in the respective line, permitting assessment 178 of each NTCP's ability to support HBV infection ( Figure 4A , center graph). In addition, to confirm 179 that the observed fluorescence signals were derived from HBV infection (and did not reflect non-180 specific background), the HBV infection assay was also performed in parallel in the presence of 181 We then performed a complementary experiment using the mNtcp backbone and substituting 191 single amino acids with the human residues for the corresponding sites; the resulting mutant mNtcps 192 were examined to determine whether any of the aa substitutions endowed cells with viral entry. Using 193 the same methods as those used in Figure 3A and B, we confirmed the protein expression as well as 194 the transporter activity of the wild-type and mutant mNtcps. Notably, all of the mNtcp derivatives 195 were expressed in HepG2 cells and provided functional bile acid uptake (to levels at least 50 % that of 196 the wild type, with activity 7-to 13-fold higher than the background level) ( Figure 3C with HBV preS1, we examined the attachment of a fluorescence-labeled preS1 peptide (preS1-208 TAMRA) to target cells expressing the wild-type NTCP or its variants ( Figure 5A by a very recent paper (44). This observation is supported by the fact that NTCPs that carry the human-244 type sequence at aa 158 (e.g., NTCP of chimpanzee, orangutan, New-World monkey, treeshrew, and 245 mouse, Figure 1 ) is known to interact with HBV preS1 (28, 44-46) (although these species except for 246 12 chimpanzee and treeshrew are not susceptible to HBV infection because of yet unknown restriction 247 mechanism in post-entry steps (44, 46)). Given that the crystal structure of NTCP has not been solved, 248 the exact mechanism whereby aa 158 facilitates HBV entry remains unknown. However, our data 249 suggest that this residue is a primary mediator of the interaction between the preS1 region of the HBV 250 envelope protein and the cell surface ( Figure 5 ). This inference would be analogous to the analysis of 251 
Materials & Methods 304
Molecular evolutionary analyses. Twenty mammalian full-length NTCP protein sequences 305 were collected from GenBank as listed in Table 1 and aligned by using MUSCLE implemented in 306 MEGA7 (57). The resulting alignment was verified manually at the amino acid level. Then, a 307
Maximum Likelihood (ML) tree of the 20 NTCP sequences was reconstructed using PhyML 3.0 (58) 308 with 1,000 bootstrap resamplings, and used for further analysis (Figure 1 Whaltham, MA). Individual mutant constructs were constructed using oligonucleotide-directed 325 mutagenesis (61). 326 16 HepG2 cells were cultured as described previously (33). To generate NTCP-expressing cells, 327
HepG2 cells were transfected with each NTCP expression plasmid using Lipofectamine 3000 (Thermo 328 Fisher Scientific) according to the manufacturer's protocol. At 24 h post-transfection, the cells were 329 trypsinized and transferred into 96-well plates; the replated cells then were subjected to preS1 binding 330 assay or virus infection assay (performed as described below) at 48 h post-transfection. 331
Western blotting. Cells were treated first with lysing buffer (1 % NP-40, 150 mM NaCl, 50 332 mM Tris-HCl pH7.5) and then with 250 U Peptide-N-Glycosidase F (PNGase F) to digest N-linked 333 oligosaccharides from glycoproteins. NTCP expression was examined by immunoblotting using 334 monoclonal anti-c-Myc antibody (Santa Cruz Biotechnology, Dallas, TX) at a 1:3,000 dilution, as 335 described previously (55). Beta-actin was detected as a loading control by using monoclonal anti-β-336 actin antibody (SIGMA, St. Louis, MO) at a 1:10,000 dilution. The chemiluminescence signals were 337 scanned with C-DiGit (LI-COR Biosciences, Lincoln, NE) and analyzed with Image Studio Lite, ver. 338 5.2 (LI-COR Biosciences). 339
NTCP transporter assay. NTCP transporter activity was measured by incubating cells with 340
[ 3 H]-taurocholic acid at 37°C for 15 min in a sodium-containing buffer to allow substrate uptake into 341 the cells. After washing to remove free [ 3 H]-taurocholic acid, cells were lysed and intracellular 342 radioactivity was measured using a LSC-6100 liquid scintillation counter (Hitachi-Aloka Medical, 343 Tokyo, Japan) as described previously (61). To measure the background signal, the same assay was 344 performed in a sodium-free buffer, in which the NTCP transporter does not function. To evaluate the 345 transporter activity of equivalent amounts of NTCP protein (normalized NTCP transporter activity), 346 we divided the value for bile acid uptake by the level of NTCP expression determined by 347 immunofluorescence analysis. Results are presented as mean ± SEM (n=3). 348 17 HBV preparation and infection. HBV inocula were derived from the culture supernatant of 349 Hep38.7-Tet cells (genotype D); these inocula were prepared as described previously (62). For the 350 HBV infection assay, HBV was infected into recipient cells at 12,000 genome equivalents (GEq)/cell 351 in the presence of 4 % polyethyleneglycol (PEG) 8000 for 16 h, followed by washing (to remove free 352 virus) and culturing the cells for an additional 12 days, according to the previously described protocol 353 (63). Indirect immunofluorescence analysis for detection of HBc was conducted to evaluate HBV 354 infection; this technique was performed essentially as described previously (64). Briefly, after fixation 355 with 4% paraformaldehyde and permeabilization with 0.3% Triton X-100, the cells were treated with 356 a polyclonal rabbit anti-HBV core antibody (Thermo Fisher Scientific) at a 1:100 dilution, and then 357 with an Alexa Fluor 594 (Thermo Fisher Scientific) -conjugated donkey anti-rabbit IgG secondary 358 antibody at a 1:500 dilution. Stained cells were photographed using a BZ-X710 microscope (Keyence, 359 Osaka, Japan), and the images were analyzed with BZ-X Analyzer 1.3.1.1 (Keyence). The relative 360 number of HBV-infected cells was determined by counting HBc-positive cells using the Hybrid Cell 361
Count module of the Keyence analyzer, and the values were normalized for the NTCP expression levels 362 determined by immunofluorescence analyses. 363 preS1 binding assay. To examine binding between the preS1 region in the large surface 364 protein of HBV (LHBs) and host cells, cells were exposed to 20 nM 6-carboxytetramethylrhodamine-365 labeled preS1 peptide (TAMRA-preS1) at 37 °C for 30 min; unbound peptide then was removed by 366 washing. To simultaneously detect Myc/His-tagged NTCP, the cells were fixed with 4 % 367 paraformaldehyde and permeabilized with 0.3% Triton X-100, and the tagged NTCP was detected with 368 a monoclonal anti-c-Myc antibody at a 1:1,200 dilution and with an Alexa Fluor 488-conjugated goat 369 anti-mouse IgG secondary antibody (Thermo Fisher Scientific) at a 1:1,000 dilution; nuclei were 370 stained with 4',6-diamidino-2-phenylindole (DAPI) at a 1:5,000 dilution. Fluorescence was quantified 371 as described above. 372 18 HDV preparation and infection. HDV was prepared from culture supernatants of Huh-7 cells 373 transfected with pSVLD3 (kindly provided by Dr. John Taylor at the Fox Chase Cancer Center) and 374 pT7HB2.7 as described previously (65, 66). The cells were inoculated with HDV at 15 GEq/cell in 375 5 % PEG 8000 for 16 h, followed by washing (to remove free virus) and culturing of the cells for an 376 additional 6 days. Total intracellular RNA was extracted and reverse transcribed using a TaqMan Gene 377
Expression Cells-to-Ct kit (Thermo Fisher Scientific) according to the manufacturer's protocol. 
